Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 Axatilimab Plus Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease
jRCT2031240468Phase 3Recruiting
- Sponsor
- Incyte
- Start
- Jan 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 2
01
Overview
A Phase 3 trial of axatilimab in chronic graft-versus-host disease (cGVHD), sponsored by Incyte. Started Jan 2025; status: recruiting.
02
Drugs
axatilimab
03
Conditions
chronic graft-versus-host disease (cGVHD)
Beyond the preview
Go deeper on jRCT2031240468.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031240468.